anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To measure human CYP2E1 with high accuracy, with high sensitivity and quickly by using an antibody which is obtained in such a way that a peptide fragment constituting the CYP2E1 as the molecular species of human cytochrome p450 is used as an antigen. SOLUTION: An antibody which is obtained in such a way that the peptide fragment (a peptide composed of the arrangement of specific amino acids in CYP2E1 protein) of CYP2E1 as one molecular species of human cytochrome p450 is used as an immunity source (an antigen) is used to measure human CYP2E1. In order to execute this method, it is required to immunize an animal by using the immunity source. As the CYP2E1 which is used as the immunity source, it is preferable to use the CYP2E1 which is derived from a human being, but the CYP2E1 which is derived from other animals can be used. In order to obtain a part (the peptide fragment) of the CYP2E1, CYP2E1 protein may be cut by using an enzyme (and/or chemically or physically cur). Alternatively, a peptide as a target may be synthesized chemically.
A computer-implemented method, apparatus, and system for servicing the needs of customers with a particular disease or disorder. A catalog of specialty items relevant to the needs of individual customers at a given stage of the disease or disorder or treatment cycle may be provided. Secure personal registries of items selected from the catalog by a customer may be provided. Experts and other third parties may recommend items for inclusion in the personal registry of the customer. Experts, customers, and/or third-parties may recommend additional items for inclusion into the catalog of specialty items. The catalog may also be updated based on sales information. Third parties may make a financial contribution or an in-kind contribution to the customer's registry. The relationship between the catalog of specialty items, recommenders, and customers, may be managed by the system while the privacy of personal customer data may be maintained.
This is a multi-center, randomized, double blind, parallel-arm, placebo controlled trial of mepolizumab. After the first 3 month blinded phase, there will be a second 3 month blinded phase where all patients receive active medication, but the dose will be lower in the subjects initially randomized to the placebo arm.

In the first arm, subjects will receive mepolizumab 300 mg SQ monthly for 3 months. In the second arm, subjects will receive a placebo SQ injection monthly for 3 months. Both groups will have the injection administered under direct observation in a Clinical \& Translational Research Center (CTRC) or other clinic to ensure proper administration and compliance. Each visit will also provide an opportunity for symptom questionnaires to be completed and for blood samples to be drawn. After 3 months (the time point where the primary outcome is assessed), all subjects initially randomized to active treatment will continue with mepolizumab dosing 300 mg SQ monthly, and will remain blinded. All subjects initially randomized to placebo will receive mepolizumab 100mg SQ monthly, and will remain blinded. Of note, no dietary changes, changes in baseline Proton Pump Inhibitor (PPI) medication dose, changes in inhaled or intranasal steroid doses, or administration or oral, topical/swallowed, or systemic steroids will be allowed during the study period. Subjects will undergo endoscopy after the first blinded phase (at 3 months) and after the second blinded phase (after 6 months).
PURPOSE: A composition containing peach leaf extract as an active ingredient is provided to effectively prevent or treat diseases related to neural cell protection. CONSTITUTION: A composition for protecting neural cells contains peach leaf extract as an active ingredient. The peach leaf extract is isolated using water, organic solvent, or mixture solvent thereof. The peach leaf extract is methanol extract. A health food contains the composition for protecting neural cells. A method for purifying a fraction of peach leaf extract comprises: a step of extracting peach leaf; a step of sequencially fractioning with hexane, chloform, and ethylacetate; a step of decompressing and drying the fraction; a step of performing silica gel column chromatography; a step of adding chloroform and methanol to obtain peach leaf extract fraction; and a step of performing TLC(thin layer chromatography) and HPLC(high performance liquid chromatography) to obtain the peach leaf extract fraction.
Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
Broadly, the present invention is directed to a method for reliably staging adenocarcinomas typified by colorectal cancer in patients who are undergoing surgery therefor. The method includes the administration of a radiolabeled tumor-associated glycoprotein (TAG) antibody (or other equivalent locator) to the cancer patient prior to surgical accession of the patient. Desirably, the present method includes surgical accession with a radiation detection probe for determining tissue exhibiting elevated levels of radiation. The preferred radiolabel is 125I, which is used to label an antibody specific to a high molecular weight glycoprotein called TAG-72. The preferred antibody is CC49, a murine monoclonal antibody of the IgG1 subclass. With radiolabeled monoclonal antibody CC49, it preferably is administered to the patient approximately 21 days (+/-4 days) prior to surgery. Following surgical excision of all such tissue which is amenable to excision, the probe is again used to identify any remaining neoplastic tissue or tissue deposits, which may or may not be subjected to further excision attempts. After all possible excision of neoplastic tissue has occurred, final counts are taken with the probe to identify residual tissue deposits not excised. The number and location of the remaining tissue deposits form the basis of the biostaging system disclosed herein.
Preoperative education will be provided by researchers to the patients on the ward before fluid intake. Solid food will be forbidden starting at 20:00 p.m, and drinking will be forbidden after 22:00 p.m the day before surgery. The Carb Group will consume carbohdrate fluid and Non-carb Group will consume equal amount of water at night and two hours before the surgery.
Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE: To provide a stable and clear aqueous drug composition containing an organic compound containing basic nitrogen and an extract of KANZOU (root of Glycyrrhiza glabra). CONSTITUTION: This drug composition contains, as active components, 0.001-1.5W/V% of an organic compound containing basic nitrogen (e.g. chlorpheniramine maleate), 0.05-5W/V% of KANZOU extract, 0.2-5W/V% of a nonionic surfactant selected from a polyoxyethylene hardened castor oil and a sucrose fatty acid ester and 0.2-5W/V% of a glycol (e.g. propylene glycol) as a stabilizer. An aqueous drug composition orally administrable as a cold remedy, remedy for rhinitis or antitussive expectorant can be produced by compounding the composition properly with other objective drug-active components, conventional additives, etc., and thermally sterilizing the mixture. The aqueous drug composition is easily producible and keeps its stability over a long period without forming precipitate with time.  The weight ratio of the polyoxyethylene hardened castor oil to the sucrose fatty acid ester is preferably 1:20 to 20: 1.
BACKGROUND: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease, whose development is associated with immune cells and persistent inflammation. Exploring the biomarkers of RA holds immense significance in terms of the prevention, diagnosis, and treatment of RA.
MATERIAL AND METHODS: The differentially expressed genes (DEGs) in RA patients and the control group were screened by limma package. Through DEGs intersection overlapping 200 inflammatory response-related genes and 2498 immune-related genes, differentially expressed immune and inflammation-related genes (DE-IIRGs) were identified. Lasso regression analysis screened RA diagnostic biomarkers and constructed PPI networks. Finally, immune infiltration analysis and drug prediction were performed.
RESULTS: A total of 20 DE-IIRGs were identified by overlapping DEGs with 2498 immune-related genes and 200 inflammatory response-related genes. These DE-IIRGs were primarily enriched in the cytokine-cytokine receptor interaction and other biological processes, and then five biomarker genes (TNFSF10, IL1R1, CXCL9, ACVR1B, and IL15) were identified. It was found that the expression levels of CXCL9, IL15, and TNFSF10 in the disease samples were significantly higher than those in the control group. These biomarker genes have more effective diagnostic potential. The RA samples exhibited significantly higher levels of cell infiltration compared to the control samples. hsa-miR-199a-5p's connections to the ACVR1B and CCR7 genes were identified by creating ceRNA networks from 20 screened DE-IIRGs. There was a connection between CCL5 and AEMA4D and hsa-miR-214-3p.
CONCLUSION: We identified immune- and inflammation-related biomarkers in RA based on bioinformatics analysis and screened TNFSF10, IL1R1, CXCL9, ACVR1B, and IL15 as diagnostic markers for RA. Key Points • TNFSF10, IL1R1, CXCL9, ACVR1B, and IL15 may be new diagnostic biomarkers for RA. • These findings may provide a theoretical basis for early RA diagnosis.
Misophonia has gained attention in scientific circles that utilise brain imaging to validate diagnoses. The condition is promoted as not merely a symptom of other psychiatric diagnoses but as a discrete clinical entity. We illustrate the social construction of the diagnostic category of misophonia through examining prominent claims in research studies that use brain imaging to substantiate the diagnosis. We show that brain images are insufficient to establish the 'brain basis for misophonia' due to both technical and logical limitations of imaging data. Often misunderstood as providing direct access to the matter of the body, brain images are mediated and manipulated numerical data (Joyce, 2005, Social Studies of Science 35(3), p. 437). Interpretations of brain scans are further shaped by social expectations and attributes considered salient to the data. Causal inferences drawn from these studies are problematic because 'misophonics' are clinically pre-diagnosed before participating. We argue that imaging cannot replace the social process of diagnosis in the case of misophonia, nor validate diagnostic measures or otherwise substantiate the condition. More broadly, we highlight both the cultural authority and inherent limitations of brain imaging in the social construction of contested diagnoses while also illustrating its role in the disaggregation of symptoms into new diagnoses.
Anticipated 15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing. Data will be analyzed for objectives 1, 4 and 5.
Group 2 will undergo unsedated peroral placement of the Bravo capsule. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour pH monitoring period.
NLRP3 inflammasome has been implicated in neutrophil polarization and extrusion of neutrophil extracellular traps (NETs) in vitro and facilitates secretion of Il1-beta (IL-1β). Permanent ligation of the left anterior descending artery was used to induce MI in WT and NLRP3-/- mice as well as in NLRP3-/- recipient mice transfused with either WT or NLRP3-/- neutrophils. NLRP3 deficiency reduced infarct size to roughly a third of WT heart injury and preserved left ventricular (LV) function at 12 h after MI as assessed by echocardiography and triphenyltetrazolium chloride staining of live tissue. Transfusion of WT but not NLRP3-/- neutrophils after MI increased infarct size in NLRP3-/- mice and significantly reduced LV function. The key features of myocardial tissue in WT neutrophil transfused recipients were increased H3Cit-positive deposits with NET-like morphology and increased tissue levels of IL-1β and plasma levels of von Willebrand Factor (VWF). Flow cytometry analysis also revealed that neutrophil NLRP3 increased the number of labeled and transfused neutrophils in the bone marrow of recipient mice following MI. Our data suggest a key role for neutrophil NLRP3 in the production of IL-1β and deposition of NETs in cardiac tissue exacerbating injury following MI. We provide evidence for a link between neutrophil NLRP3 and VWF release likely enhancing thromboinflammation in the heart. Neutrophil NLRP3 deficiency conferred similar cardioprotective effects to general NLRP3 deletion in MI rendering anti-neutrophil NLRP3 therapy a promising target for early cardioprotective treatment.
Indigo naturalis is an effective treatment for ulcerative colitis. However, long-term use of indigo naturalis causes adverse events, such as pulmonary hypertension. The natural history of patients with ulcerative colitis who discontinued indigo naturalis after induction therapy is unknown. Moreover, the clinical features of patients who relapsed within 52 weeks after the discontinuation of indigo naturalis are unclear. This study aimed to assess the clinical outcomes of patients with ulcerative colitis after discontinuation of indigo naturalis and to identify potential markers responsible for relapse. This single-center retrospective study investigated the follow-up of 72 patients who achieved a clinical response 8 weeks after indigo naturalis treatment. We observed relapse in patients with ulcerative colitis after the discontinuation of indigo naturalis. We analyzed the factors predicting long-term outcomes after discontinuation of indigo naturalis. Relapse was observed in 24%, 57%, and 71% of patients at 8, 26, and 52 weeks, respectively. There were no predictive markers in patients who relapsed within 52 weeks after the discontinuation of indigo naturalis. The ulcerative colitis relapse rate after indigo naturalis discontinuation was high. Follow-up treatment is required after the discontinuation of indigo naturalis in patients with ulcerative colitis.
PURPOSE: Pharmacy chains can differ with respect to the characteristics of their patient populations as well as their nonprescription products, services, and practices, and thus may serve as a surrogate for potential unmeasured confounding in observational studies of prescription drugs. This study evaluates whether a single-source drug can have different patient outcomes based on the dispensing pharmacy chain.
METHODS: Separate analyses for two anticoagulant drugs, rivaroxaban and apixaban, were conducted using Medicare Fee-for-Service claims evaluating the association between dispensing pharmacy chain and outcomes of acute myocardial infarction, ischemic stroke, intracranial hemorrhage, gastrointestinal (GI) bleeding, all-cause mortality, and major GI bleeding. Inverse probability of treatment weighting (IPTW) was used to balance baseline covariates across pharmacy chain cohorts, and outcome association was assessed with a Cox Proportional Hazards model.
RESULTS: We observed no differences in outcomes across pharmacy chains for apixaban recipients. Rivaroxaban recipients from pharmacy chain C, however, had lower rates of GI bleeding (adjusted HR 0.83; 95% CI 0.69-1.00) and ischemic stroke (adjusted HR 0.57; 95% CI 0.38-0.87) as compared to chain A in primary analyses with a 3-day grace period. The results moved closer to the null when 14- and 30-day grace periods were implemented.
CONCLUSIONS: These results suggest that dispensing pharmacy chains may have the potential to act as a confounder of associations between drug exposure and outcome in some observational studies. Additional studies of potential confounding by pharmacy chain are needed. Further evaluation of potential pharmacy chain effects on safe use would be of value.
The copayment amount due the participating pharmacy a member patient for preparing a compounded or other specialty medication as determined by the Pharmacy Benefit Manager is ascertained by the system. The system calculates the portion of copayment amount that the system is obligated to pay the pharmacy based upon the products used in the preparation of the prescribed medicine obtained by the pharmacy from an affiliated supplier. The system advises the pharmacy of the copayment amount to be paid by the patient. The system then pays the pharmacy the calculated portion of the copayment amount that the system is obligated to pay. The system collects, aggregates and stores data about the transactions between patients and participating pharmacies. It may enhance the stored data by connecting with third party data bases. The data is customized and sold to the participating pharmacies or outside entities.
Plant viruses have multiple strategies to counter and evade the host's antiviral immune response. However, limited research has been conducted on the antiviral defense mechanisms commonly targeted by distinct types of plant viruses. In this study, we discovered that NUCLEAR FACTOR-YC (NF-YC) and NUCLEAR FACTOR-YA (NF-YA), 2 essential components of the NF-Y complex, were commonly targeted by viral proteins encoded by 2 different rice (Oryza sativa L.) viruses, rice stripe virus (RSV, Tenuivirus) and southern rice black streaked dwarf virus (SRBSDV, Fijivirus). In vitro and in vivo experiments showed that OsNF-YCs associate with OsNF-YAs and inhibit their transcriptional activation activity, resulting in the suppression of OsNF-YA-mediated plant susceptibility to rice viruses. Different viral proteins RSV P2 and SRBSDV SP8 directly disrupted the association of OsNF-YCs with OsNF-YAs, thereby suppressing the antiviral defense mediated by OsNF-YCs. These findings suggest an approach for conferring broad-spectrum disease resistance in rice and reveal a common mechanism employed by viral proteins to evade the host's antiviral defense by hindering the antiviral capabilities of OsNF-YCs.
The present invention relates to sterility in an operation room. In order to provide improvement for maintaining the sterility, a device (10) for monitoring sterility in an operation room is provided that comprises an image supply (12), a data processor (14) and an output (16). The image supply is configured to provide a stream of image data (18) representing activities during an interventional procedure in the operating room. The data processor is configured to determine at least one sterile zone and at least one non-sterile zone within the operating room based on the stream of image data and to detect activity in the stream of image data that results in sterility breach of the at least one sterile zone and to generate warning data (20) indicating a potential sterility breach. The output is configured to provide the warning data. In an example, a camera grabbing system is provided and various specific smart actions and warnings in the cath lab environment are provided, based on camera observations. The actions are sterility related. The system provides sterility related monitoring without the need for any further input regarding actual scenery data, except for the image stream. In an example, the image feed by the stream of image data is the only required source of information.
The patient will undergo first surgery under general anesthesia for the collection of the cortical biopsy (5x5x5 mm biopsy of non-dominant frontal cortex). After the production of ANCE from the cortical biopsy, which last 8 to 12 weeks, the patient will undergo a second neurosurgery, for the stereotaxic reimplantation of ANCE under general anesthesia.
Following a single oral dose of 20 mg/kg no lethality occurred in rats and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Lisinopril can be removed by hemodialysis. (See Error! Hyperlink reference not valid. .)
Increased dietary phosphate consumption intensifies renal phosphate burden. Several mechanisms for phosphate-induced renal tubulointerstitial fibrosis have been reported. Considering the dual nature of phosphate as both a potential renal toxin and an essential nutrient for the body, kidneys may possess inherent protective mechanisms against phosphate overload, rather than succumbing solely to injury. However, there is limited understanding of such mechanisms. To identify these mechanisms, we conducted single-cell RNA sequencing (scRNA-seq) analysis of the kidneys of control and dietary phosphate-loaded (Phos) mice at a time point when the Phos group had not yet developed tubulointerstitial fibrosis. scRNA-seq analysis identified the highest number of differentially expressed genes in the clusters belonging to proximal tubular epithelial cells (PTECs). Based on these differentially expressed genes, in silico analyses suggested that the Phos group activated peroxisome proliferator-activated receptor-α (PPAR-α) and fatty acid β-oxidation (FAO) in the PTECs. This activation was further substantiated through various experiments, including the use of an FAO activity visualization probe. Compared with wild-type mice, Ppara knockout mice exhibited exacerbated tubulointerstitial fibrosis in response to phosphate overload. Experiments conducted with cultured PTECs demonstrated that activation of the PPAR-α/FAO pathway leads to improved cellular viability under high-phosphate conditions. The Phos group mice showed a decreased serum concentration of free fatty acids, which are endogenous PPAR-α agonists. Instead, experiments using cultured PTECs revealed that phosphate directly activates the PPAR-α/FAO pathway. These findings indicate that noncanonical metabolic reprogramming via endogenous activation of the PPAR-α/FAO pathway in PTECs is essential to counteract phosphate toxicity.NEW & NOTEWORTHY This study revealed the activation of peroxisome proliferator-activated receptor-α and fatty acid β-oxidation in proximal tubular epithelial cells as an endogenous mechanism to protect the kidney from phosphate toxicity. These findings highlight noncanonical metabolic reprogramming as a potential target for suppressing phosphate toxicity in the kidneys.